{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:38:11Z","timestamp":1773956291761,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016032","name":"Nederlandse Cystic Fibrosis Stichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022854","name":"European Cystic Fibrosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022854","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010109","name":"Medizinische Universit\u00e4t Graz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000292","name":"Cystic Fibrosis Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000292","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["MUHLEB22A"],"award-info":[{"award-number":["MUHLEB22A"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.rmed.2025.108465","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T01:36:47Z","timestamp":1761788207000},"page":"108465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Changes in use of inhaled chronic antibiotics in the European CF population: an ECFS patient registry study"],"prefix":"10.1016","volume":"250","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6391-1598","authenticated-orcid":false,"given":"Marianne S.","family":"Muhlebach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lutz","family":"Naehrlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siobh\u00e1n B.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0932-2757","authenticated-orcid":false,"given":"Annalisa","family":"Orenti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6225-2989","authenticated-orcid":false,"given":"Simone","family":"Gambazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.rmed.2025.108465_bib1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ppul.2009","article-title":"Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition","volume":"32","author":"Kosorok","year":"2001","journal-title":"Pediatr. Pulmonol."},{"issue":"2","key":"10.1016\/j.rmed.2025.108465_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J. Cyst. Fibros."},{"issue":"10","key":"10.1016\/j.rmed.2025.108465_bib3","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1513\/AnnalsATS.201404-166OC","article-title":"Cystic fibrosis foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection","volume":"11","author":"Mogayzel","year":"2014","journal-title":"Ann. Am Thorac. Soc."},{"issue":"3","key":"10.1016\/j.rmed.2025.108465_bib4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jcf.2019.04.006","article-title":"Patient engagement to prioritise CF research: inclusive or selective?","volume":"18","author":"Rowbotham","year":"2019","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.rmed.2025.108465_bib5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jcf.2019.06.005","article-title":"Do current clinical trials in cystic fibrosis match the priorities of patients and clinicans? A systematic review","volume":"19","author":"Kalaitzis","year":"2020","journal-title":"J. Cyst. Fibros."},{"issue":"5","key":"10.1016\/j.rmed.2025.108465_bib6","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jcf.2018.01.008","article-title":"Risk factors for persistent Aspergillus respiratory isolation in cystic fibrosis","volume":"17","author":"Hong","year":"2018","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.rmed.2025.108465_bib7","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75886-w","article-title":"Risk factors for respiratory Aspergillus fumigatus in German cystic fibrosis patients and impact on lung function","volume":"10","author":"Duesberg","year":"2020","journal-title":"Sci. Rep."},{"issue":"Suppl 2","key":"10.1016\/j.rmed.2025.108465_bib8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S1569-1993(02)00005-X","article-title":"Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis","volume":"1","author":"Govan","year":"2002","journal-title":"J. Cyst. Fibros."},{"issue":"9","key":"10.1016\/j.rmed.2025.108465_bib9","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.4187\/respcare.08671","article-title":"The role of suboptimal concentrations of nebulized tobramycin in driving antimicrobial resistance in Pseudomonas aeruginosa isolates in cystic fibrosis","volume":"66","author":"Moore","year":"2021","journal-title":"Respir. Care"},{"issue":"3","key":"10.1016\/j.rmed.2025.108465_bib10","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00449-2022","article-title":"Risk factors for forced expiratory volume in 1 s decline in European patients with cystic fibrosis: data from the European cystic fibrosis society patient registry","volume":"9","author":"Hatziagorou","year":"2023","journal-title":"ERJ Open Res."},{"issue":"3","key":"10.1016\/j.rmed.2025.108465_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01241-2023","article-title":"Cystic fibrosis in Europe: improved lung function and longevity - reasons for cautious optimism, but challenges remain","volume":"63","author":"Kerem","year":"2024","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2025.108465_bib13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jcf.2022.08.010","article-title":"Prevalence, trends and outcomes of long-term inhaled antibiotic treatment in people with cystic fibrosis without chronic Pseudomonas aeruginosa infection - a European cystic fibrosis patient registry data analysis","volume":"22","author":"Orenti","year":"2023","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.rmed.2025.108465_bib15","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1080\/13696998.2024.2373000","article-title":"Clinical, economic, and societal burden of cystic fibrosis and the impact of the CFTR modulator, lumacaftor\/ivacaftor: an assessment using linked registry data in Sweden","volume":"27","author":"Lindblad","year":"2024","journal-title":"J. Med. Econ."},{"issue":"1","key":"10.1016\/j.rmed.2025.108465_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"2","author":"Lee","year":"2003","journal-title":"J. Cyst. Fibros."},{"issue":"8","key":"10.1016\/j.rmed.2025.108465_bib17","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/thx.2005.049536","article-title":"Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis","volume":"61","author":"Kappler","year":"2006","journal-title":"Thorax"},{"issue":"10","key":"10.1016\/j.rmed.2025.108465_bib18","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1128\/jcm.25.10.1830-1836.1987","article-title":"Diagnosis of chronic Pseudomonas aeruginosa infection in cystic fibrosis by enzyme-linked immunosorbent assay","volume":"25","author":"Pedersen","year":"1987","journal-title":"J. Clin. Microbiol."},{"issue":"4","key":"10.1016\/j.rmed.2025.108465_bib19","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1034\/j.1399-3003.2000.16d30.x","article-title":"Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus","volume":"16","author":"D\u00f6ring","year":"2000","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.rmed.2025.108465_bib20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/1753465816680573","article-title":"Best practices in the treatment of early cystic fibrosis lung disease","volume":"11","author":"Proesmans","year":"2017","journal-title":"Ther. Adv. Respir. Dis."},{"issue":"6","key":"10.1016\/j.rmed.2025.108465_bib21","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.108465_bib22","series-title":"Language and Environment for Statistical Computing","author":"R-Core","year":"2024"},{"issue":"1","key":"10.1016\/j.rmed.2025.108465_bib24","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jcf.2023.05.007","article-title":"The prevalence of children in the UK cystic fibrosis registry on long term anti-Pseudomonas aeruginosa (PA) inhaled antibiotics who become culture negative for PA and a survey of practice for discontinuing treatment","volume":"23","author":"Gilchrist","year":"2024","journal-title":"J. Cyst. Fibros."},{"issue":"S1569-1993(25)01579-6","key":"10.1016\/j.rmed.2025.108465_bib25","article-title":"Factors associated with sustained Pseudomonas aeruginosa infection following elexacaftor\/tezacaftor\/ivacaftor treatment: Real-World data from the European cystic fibrosis society patient registry","volume":"11","author":"Pollak","year":"2025","journal-title":"J. Cyst. Fibros."},{"issue":"1","key":"10.1016\/j.rmed.2025.108465_bib26","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1128\/AAC.04123-14","article-title":"In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients","volume":"59","author":"Ratjen","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.rmed.2025.108465_bib27","article-title":"Nebulized levofloxacin for chronic Burkholderia cenocepacia pulmonary infection in cystic fibrosis: a case report","volume":"40","author":"Dagenais","year":"2022","journal-title":"Respir Med. Case Rep."},{"issue":"1","key":"10.1016\/j.rmed.2025.108465_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12890-018-0594-8","article-title":"Implementation of a successful eradication protocol for Burkholderia Cepacia complex in cystic fibrosis patients","volume":"18","author":"Garcia","year":"2018","journal-title":"BMC Pulm. Med."},{"issue":"3","key":"10.1016\/j.rmed.2025.108465_bib29","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00055-2023","article-title":"Eradication of Burkholderia cepacia complex in cystic fibrosis patients with inhalation of amiloride and tobramycin combined with oral cotrimoxazole","volume":"9","author":"Akkerman-Nijland","year":"2023","journal-title":"ERJ Open Res."},{"issue":"4","key":"10.1016\/j.rmed.2025.108465_bib30","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jcf.2017.02.008","article-title":"Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection","volume":"16","author":"Waters","year":"2017","journal-title":"J. Cyst. Fibros."},{"issue":"5","key":"10.1016\/j.rmed.2025.108465_bib31","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jcf.2025.04.007","article-title":"Association between inhaled antibiotic use and treatment-emergent organisms among Canadian people with cystic fibrosis","volume":"24","author":"Cogen","year":"2025","journal-title":"J. Cyst. Fibros."},{"issue":"3 Suppl","key":"10.1016\/j.rmed.2025.108465_bib32","article-title":"Microbiological and immunologic considerations with aerosolized drug delivery","volume":"120","author":"LiPuma","year":"2001","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2025.108465_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2023-002049","article-title":"Considerations for the use of inhaled antibiotics for Pseudomonas aeruginosa in people with cystic fibrosis receiving CFTR modulator therapy","volume":"11","author":"Burgel","year":"2024","journal-title":"BMJ Open Respir Res."},{"issue":"167","key":"10.1016\/j.rmed.2025.108465_bib34","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0154-2022","article-title":"Role of inhaled antibiotics in the era of highly effective CFTR modulators","volume":"32","author":"Elborn","year":"2023","journal-title":"Eur. Respir. Rev."},{"issue":"1","key":"10.1016\/j.rmed.2025.108465_bib35","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s00431-024-05905-9","article-title":"Antibiotic treatment of bacterial lung infections in cystic fibrosis","volume":"184","author":"Taccetti","year":"2024","journal-title":"Eur. J. Pediatr."},{"issue":"174","key":"10.1016\/j.rmed.2025.108465_bib36","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0068-2024","article-title":"Changing profile of bacterial infection and microbiome in cystic fibrosis: when to use antibiotics in the era of CFTR-modulator therapy","volume":"33","author":"Milczewska","year":"2024","journal-title":"Eur. Respir. Rev."},{"issue":"1","key":"10.1016\/j.rmed.2025.108465_bib37","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jcf.2024.09.017","article-title":"Changes in factors associated with inhaled antibiotic prescriptions for people with cystic fibrosis over time in the U.S","volume":"24","author":"Muhlebach","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.rmed.2025.108465_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2023.102214","article-title":"Chronic inhaled antibiotic therapy in people with cystic fibrosis with Pseudomonas aeruginosa infection in Germany","volume":"80","author":"Naehrig","year":"2023","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.rmed.2025.108465_bib39","series-title":"10th European Conference on Rare Diseases & Orphan Products","article-title":"The European cystic fibrosis society patient registry's data quality programme","author":"van Rens","year":"2020"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125005281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125005281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:22:31Z","timestamp":1773940951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125005281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":36,"alternative-id":["S0954611125005281"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108465","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in use of inhaled chronic antibiotics in the European CF population: an ECFS patient registry study","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.108465","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108465"}}